Assyro AI

Purple Book product · Reference 351(a)

Rituxan Hycela

rituximab and hyaluronidase human

351(a)BLA 761064RxLicensed Genentech, Inc.

Jun 22, 2017

Approved

Reference 351(a)

License type

Rx

Marketing

None

Listed patents

Rituxan Hycela (rituximab and hyaluronidase human) is Genentech, Inc.'s FDA-licensed reference biologic, approved under a 351(a) BLA in 2017. No biosimilars referencing Rituxan Hycela are listed in the Purple Book yet.

Sourced from the FDA Purple Book · verified Jul 02, 2026

Key dates

  1. Approval

    Approval date of this BLA submission.

    Jun 22, 2017

    9 yr 2 mo ago

  2. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    Jun 22, 2024

    2 yr 1 mo ago

  3. Today

Pharmaceutical detail

Strength

1,600MG/13.4ML; 26,800UNITS/13.4ML (120MG/2,000UNITS/ML)

Dosage form

Injection

Route

Subcutaneous

Presentation

Single-Dose Vial

Center

CDER

License number

1048

Product number

002

Submission type

Original

Supplement number

Not listed

Change type

Not listed

Reference product family

View full family

This is the reference (originator) product. No biosimilars or interchangeables reference it in the Purple Book yet.

1 additional BLA record for this product (other strengths or presentations) are in the same reference family.

Patent list

No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.

Source provenance

Source kind · Advanced Search
Checked Jul 02, 2026
  • advanced-searchAdvanced Search · Jul 02, 2026
  • monthly-downloadMonthly download · Jul 02, 2026

Change history

  • v4Jul 02, 2026
  • v3Jul 02, 2026
  • v2Jul 02, 2026

Frequently asked questions

Does Rituxan Hycela have approved biosimilars?

No 351(k) biosimilars or interchangeable biosimilars referencing Rituxan Hycela are listed in the FDA Purple Book yet.

What is Rituxan Hycela's BLA number?

Rituxan Hycela is licensed under BLA 761064, held by Genentech, Inc..

When was Rituxan Hycela approved by the FDA?

Rituxan Hycela was approved by the FDA on Jun 22, 2017.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.